Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics

H Yamaguchi, JM Hsu, WH Yang… - Nature Reviews Clinical …, 2022 - nature.com
Antagonistic antibodies targeting the inhibitory immune-checkpoint receptor PD-1 or its
ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve …

[HTML][HTML] Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer

H Zhang, Z Dai, W Wu, Z Wang, N Zhang… - Journal of Experimental …, 2021 - Springer
The cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4)/B7 and programmed death 1
(PD-1)/programmed cell death-ligand 1 (PD-L1) are two most representative immune …

[HTML][HTML] Mechanisms controlling PD-L1 expression in cancer

JH Cha, LC Chan, CW Li, JL Hsu, MC Hung - Molecular cell, 2019 - cell.com
The engagement of programmed cell death protein 1 (PD-1; encoded by the PDCD1 gene)
receptor expressed on activated T cells and its ligand, programmed death-ligand 1 (PD-L1; …

Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials

A Lin, CJ Giuliano, A Palladino, KM John… - Science translational …, 2019 - science.org
Ninety-seven percent of drug-indication pairs that are tested in clinical trials in oncology
never advance to receive US Food and Drug Administration approval. While lack of efficacy …

[HTML][HTML] Emerging concepts for immune checkpoint blockade-based combination therapies

R Zappasodi, T Merghoub, JD Wolchok - Cancer cell, 2018 - cell.com
Checkpoint blockade has formally demonstrated that reactivating anti-tumor immune
responses can regress tumors. However, this only occurs in a fraction of patients …

HDAC6 as privileged target in drug discovery: A perspective

S Pulya, SA Amin, N Adhikari, S Biswas, T Jha… - Pharmacological …, 2021 - Elsevier
Abstract HDAC6, a class IIB HDAC isoenzyme, stands unique in its structural and
physiological functions. Besides histone modification, largely due to its cytoplasmic …

[HTML][HTML] The extrinsic and intrinsic roles of PD-L1 and its receptor PD-1: implications for immunotherapy treatment

K Hudson, N Cross, N Jordan-Mahy… - Frontiers in …, 2020 - frontiersin.org
Programmed death-ligand 1 (PD-L1) is an immune checkpoint inhibitor that binds to its
receptor PD-1 expressed by T cells and other immune cells to regulate immune responses; …

[HTML][HTML] Histone deacetylase 6 in cancer

T Li, C Zhang, S Hassan, X Liu, F Song, K Chen… - Journal of hematology & …, 2018 - Springer
Histone acetylation and deacetylation are important epigenetic mechanisms that regulate
gene expression and transcription. Histone deacetylase 6 (HDAC6) is a unique member of …

[HTML][HTML] Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations

I Zerdes, A Matikas, J Bergh, GZ Rassidakis… - Oncogene, 2018 - nature.com
The programmed death protein 1 (PD-1) and its ligand (PD-L1) represent a well-
characterized immune checkpoint in cancer, effectively targeted by monoclonal antibodies …

[HTML][HTML] The transcription factor Bhlhe40 programs mitochondrial regulation of resident CD8+ T cell fitness and functionality

C Li, B Zhu, YM Son, Z Wang, L Jiang, M Xiang, Z Ye… - Immunity, 2019 - cell.com
Tissue-resident memory CD8+ T (Trm) cells share core residency gene programs with tumor-
infiltrating lymphocytes (TILs). However, the transcriptional, metabolic, and epigenetic …